Dupilumab

Summary

Dupilumab (CHEMBL2108675) is an approved antibody (ATC D11AH05) targeting IL4R; indicated across 35 conditions including atopic eczema and nasal cavity polyp.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: D11AH05
• Targets: 1 (IL4R)
• Indications: 35 conditions
• Clinical trials: 218

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108675
Name	Dupilumab
Type	Antibody
Max phase	4
ATC	D11AH05

Also known as: Dupilumab, Dupixent, REGN-668, REGN668, Regn668, sar231893, SAR-231893, SAR231893, DUPILUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
IL4R	Interleukin-4 receptor subunit α	Binding	11.06	0.4%	P24394

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): IL4R.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Interleukin-4 and Interleukin-13 signaling	1	IL4R
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	1	IL4R

Dominant GO biological processes

GO term	Targets
production of molecular mediator involved in inflammatory response	1
positive regulation of immunoglobulin production	1
immune response	1
signal transduction	1
immunoglobulin mediated immune response	1
positive regulation of chemokine production	1
interleukin-4-mediated signaling pathway	1
defense response to protozoan	1
positive regulation of macrophage activation	1
positive regulation of mast cell degranulation	1
T-helper 1 cell differentiation	1
T-helper 2 cell differentiation	1
negative regulation of T-helper 1 cell differentiation	1
positive regulation of T-helper 2 cell differentiation	1
positive regulation of cold-induced thermogenesis	1

Indications & clinical

Indications

35 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atopic eczema	4	MONDO:0004980	EFO:0000274
nasal cavity polyp	4	MONDO:0006314	EFO:1000391
sinusitis	4	MONDO:0005961	EFO:0007486
asthma	4	MONDO:0004979	MONDO:0004979
esophageal disorder	4	MONDO:0003749	EFO:0009544
prurigo	4	MONDO:0021739	MONDO:0021739
eosinophilic esophagitis	3	MONDO:0005361	EFO:0004232
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
neurodermatitis	3	MONDO:0006585	EFO:1000740
dermatitis	3	MONDO:0002406	MONDO:0002406
cold urticaria	3	MONDO:0022799	EFO:1001881
alopecia areata	2	MONDO:0005340	EFO:0004192
respiratory system disorder	2	MONDO:0005087	EFO:0000684
urticaria	2	MONDO:0005492	EFO:0005531
allergic rhinitis	2	MONDO:0011786	EFO:0005854
angioedema	2	MONDO:0010481	EFO:0005532
atopic conjunctivitis	2	MONDO:0005642	EFO:0007141
bullous pemphigoid	2	MONDO:0019082	EFO:0007187
localized scleroderma	2	MONDO:0019562	EFO:1001361
allergic bronchopulmonary aspergillosis	2	MONDO:0015243	EFO:0007140
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
keloid	2	MONDO:0005348	EFO:0004212
Netherton syndrome	2	MONDO:0009735	MONDO:0009735
ulcerative colitis	2	MONDO:0005101	EFO:0000729
hypereosinophilic syndrome	2	MONDO:0015691	EFO:1001467
allergic disease	2	MONDO:0005271	MONDO:0005271
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
food allergy	1	MONDO:0700226	EFO:1001890
skin disorder	0	MONDO:0005093	EFO:0000701

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 218.

Phase distribution

Phase	Trials
PHASE4	52
PHASE3	48
PHASE2	48
Not specified	45
PHASE1	14
EARLY_PHASE1	5
PHASE2/PHASE3	3
PHASE1/PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03694158	PHASE4	ACTIVE_NOT_RECRUITING	Investigating Dupilumab’s Effect in Asthma by Genotype
NCT03935971	PHASE4	ACTIVE_NOT_RECRUITING	The Effects of Dupilumab on Allergic Contact Dermatitis
NCT04743791	PHASE4	RECRUITING	Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
NCT04869436	PHASE4	RECRUITING	Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
NCT05042258	PHASE4	RECRUITING	Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT05097287	PHASE4	ACTIVE_NOT_RECRUITING	Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05268107	PHASE4	RECRUITING	Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05285839	PHASE4	RECRUITING	Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05642208	PHASE4	ACTIVE_NOT_RECRUITING	Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
NCT05858619	PHASE4	RECRUITING	Molecular Signatures of Cutaneous Dupilumab Response
NCT05942222	PHASE4	ACTIVE_NOT_RECRUITING	A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT05983068	PHASE4	ACTIVE_NOT_RECRUITING	A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
NCT06004986	PHASE4	RECRUITING	DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
NCT06101095	PHASE4	ACTIVE_NOT_RECRUITING	A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
NCT06352073	PHASE4	ACTIVE_NOT_RECRUITING	Dupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT06385236	PHASE4	RECRUITING	Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
NCT06465732	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients
NCT06556264	PHASE4	NOT_YET_RECRUITING	Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps
NCT06572228	PHASE4	ACTIVE_NOT_RECRUITING	Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06665971	PHASE4	RECRUITING	Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT06750471	PHASE4	ACTIVE_NOT_RECRUITING	Dupixent Study for Alternate Administration
NCT06818019	PHASE4	NOT_YET_RECRUITING	Withdrawal of Dupilumab in Severe Asthma
NCT07053423	PHASE4	RECRUITING	A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07587658	PHASE4	NOT_YET_RECRUITING	This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
NCT03293030	PHASE4	COMPLETED	Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
NCT03389893	PHASE4	TERMINATED	Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
NCT03667014	PHASE4	COMPLETED	The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
NCT04033367	PHASE4	COMPLETED	SAR231893-LPS15497- Dupilumab Effect on Sleep in AD Patients
NCT04203797	PHASE4	COMPLETED	A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
NCT04400318	PHASE4	COMPLETED	The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
NCT04442256	PHASE4	UNKNOWN	Effect of Dupilumab on Aspirin Intolerance
NCT04447417	PHASE4	COMPLETED	Dupilumab Skin Barrier Function Study in Atopic Dermatitis
NCT04502862	PHASE4	COMPLETED	A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
NCT04718870	PHASE4	COMPLETED	Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
NCT04823130	PHASE4	COMPLETED	Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
NCT04895423	PHASE4	UNKNOWN	Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood
NCT04988022	PHASE4	COMPLETED	Dupilumab in the Treatment of Keloids
NCT04996485	PHASE4	UNKNOWN	Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
NCT04998604	PHASE4	COMPLETED	EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).